Heterocyclic compounds as inhibitors of beta-lactamases

a technology of beta-lactamases and heterocyclic compounds, which is applied in the direction of antibacterial agents, drug compositions, biocides, etc., to achieve the effect of inhibiting the production of -lactamases

Inactive Publication Date: 2009-08-27
FOREST LAB HLDG LTD
View PDF14 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is well known that the enzymatic inactivation of antibiotics of β-lactamine type, whether compounds of penicillin or cephalosporin type, in the treatment of bacterial infections is a obstacle for this type of compound.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic compounds as inhibitors of beta-lactamases
  • Heterocyclic compounds as inhibitors of beta-lactamases
  • Heterocyclic compounds as inhibitors of beta-lactamases

Examples

Experimental program
Comparison scheme
Effect test

example 1

cis diphenylmethyl 7-oxo-6-oxa-1-azabicyclo[3.2.1]octane-4-propanoate

[0144]3.16 g (10.6 mmoles) of the hydrochloride of 3-oxo-1-(phenylmethyl)-4-piperidinepropanoic acid (M=297.7 g) (described in the Japanese Patent Application J54098-772) is mixed with 100 ml of ethanol and the reaction medium is cooled down to 10° C. 1.84 g of NaBH4 is added over 15 minutes, under a stream of nitrogen, whilst maintaining the temperature between 8 and 13° C. The temperature is allowed to rise to ambient temperature and left in contact for 1 hour 30 minutes. Another 380 mg of NaBH4 is added and the reaction medium is left overnight at ambient temperature.

[0145]The solvent is evaporated off under reduced pressure, followed by taking up in 50 ml of water and adjusting the pH from 10 to 2 using concentrated hydrochloric acid. Evaporation is again carried out under reduced pressure. The solid residue (approximately 10.8 g) is washed twice with 100 ml of ethanol then the solvent is evaporated off under r...

example 1a

cis-7-oxo-6-oxa-1-azabicyclo[3.2.1]octane-4-propanoic acid

[0170]176 mg (0.482 mmoles) of the product obtained previously is dissolved in 10 ml of acetone. 90 mg of Pd / C at 10% by weight is added.

[0171]The reaction medium is left to react under a hydrogen atmosphere at normal pressure for 3 hours. Another 25 mg of catalyst is added and the reaction is left to continue for 1 hour 15 minutes.

[0172]The catalyst is filtered then the solvent is evaporated off under reduced pressure in order to obtain 146 mg of product.

[0173]The medium is reacted in 10 ml of acetone with 35 mg of Pd / C at 10% by weight under a hydrogen atmosphere and the reaction is left for 1 hour to complete.

[0174]The catalyst is then separated by filtration and the filtrate is evaporated under reduced pressure. 137 mg of crude product is obtained which is crystallized from a mixture of ethyl ether and petroleum ether. In this way 75 mg of the sought product (M=199 g) is obtained, i.e. a yield of 78%.

[0175]1H NMR

[0176]In ...

example 2

Trans diphenylmethyl 7-oxo-6-oxa-1-azabicyclo[3.2.1]octan-4-acetate

[0180]94 mg (0.259 mmoles) of the compound trans diphenylmethyl 3-hydroxy-4-piperidine-acetate hydrochloride (M=361.87 g) (described in Eur. J. Med. Chem—Chim. Ther—1982-17(6)531-5) and 7 ml of dichloromethane are mixed under an inert atmosphere.

[0181]The reaction medium is cooled down using an ice bath and 19 μl of diphosgene is injected. Agitation is carried out for 25 minutes, then 72 μl of TEA is injected. Agitation is carried out at ambient temperature for 30 minutes and the solvent is evaporated off under reduced pressure, followed by taking up in 7 ml of toluene.

[0182]36 μl of TEA then 31 mg of DMAP are added.

[0183]Heating is carried out for 15 minutes at 100° C., then the reaction medium is left to return to ambient temperature, followed by washing twice with 4 ml of 10% tartaric acid in water, then with 4 ml of water saturated with sodium chloride.

[0184]After drying over magnesium sulphate, filtration is car...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.

Description

[0001]This application is a continuation of International Application No. PCT / FR03 / 00243 filed Jan. 27, 2003, which claims the benefit of priority of French Application No. 02 00951, filed Jan. 28, 2002.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The invention relates to heterocyclic compounds, endowed with beta-lactamase inhibitory properties, and therefore are of interest in combating infectious diseases or in the prevention of them, in the form of a combination with various antibiotic compounds of β-lactamine type, in order to reinforce their effectiveness in combating the pathogenic bacteria which produce β-lactamases.[0004]2. Description of the Art[0005]It is well known that the enzymatic inactivation of antibiotics of β-lactamine type, whether compounds of penicillin or cephalosporin type, in the treatment of bacterial infections is a obstacle for this type of compound. This inactivation consists of a degradation process of the β-lactamines and constitutes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/55A61K31/397C07D487/08A61K31/4188A61K31/439A61K31/519A61P31/04A61P43/00C07D471/08C07D498/08
CPCA61K31/439A61K31/55A61K2300/00A61P31/00A61P31/04A61P43/00Y02A50/30A61K31/4995A61K31/435
Inventor ASZODI, JOZSEFFROMENTIN, CLAUDELAMPILAS, MAXIMEROWLANDS, DAVID ALAN
Owner FOREST LAB HLDG LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap